Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
06 Setembro 2023 - 9:05AM
Business Wire
- First blood-only liquid biopsy test for minimal residual
disease now covered for patients with stage II or III colorectal
cancer
- Test used after surgery or curative treatment to inform
physician decisions about adjuvant therapy and to monitor for
disease progression, recurrence or relapse
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology
company, announced today that Geisinger Health Plan now offers
coverage for the Guardant Reveal™ minimal residual disease (MRD)
test. Guardant Reveal is a blood test that detects circulating
tumor DNA (ctDNA) in blood after treatment, including surgery, to
help oncologists identify cancer patients with residual or
recurring disease who may benefit most from adjuvant therapy or
surveillance. It is the first blood-only liquid biopsy test
commercially available for MRD testing.
Geisinger is providing coverage for the Guardant Reveal test for
individuals with stage II or III colorectal cancer after curative
treatment (including surgery) to inform physician decisions about
post-treatment therapy and to monitor for disease progression,
recurrence or relapse. The frequency of testing covered is aligned
with monitoring guidelines established by the National
Comprehensive Cancer Network for colorectal cancer. It includes the
initial ctDNA test 4 to 6 weeks after surgery (or 2 to 4 weeks
after completion of systemic therapy) and thereafter every 3 to 6
months for the first two years, and every 6 to 12 months for the
following 3 years.
“We are pleased that Geisinger Health Plan has taken this
important step to make blood testing for residual disease more
accessible to its members,” said Helmy Eltoukhy, Guardant Health
chairman and co-CEO. “This decision will help oncologists make more
informed decisions about treatment and monitoring for colorectal
cancer patients and survivors, to help improve their outcomes.”
Minimal residual disease refers to a subclinical measure of
cancer burden that remains during and following treatment. A
patient’s MRD status is a reliable indicator of clinical outcome
and response to therapy and can be used for risk stratification and
to guide treatment options when used in conjunction with other
clinical data.
The Geisinger Health Plan provides coverage for more than half a
million members. This policy decision adds to the payor coverage of
Guardant Reveal, which received Medicare coverage in August 2022
and additional commercial payor coverage in July 2023.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY® tests for advanced stage cancer, and Guardant
Reveal™ for early-stage cancer. The Guardant Health screening
portfolio, including the commercially launched Shield™ test, aims
to address the needs of individuals eligible for cancer screening.
For more information, visit guardanthealth.com and follow the
company on LinkedIn and X (Twitter).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230906087978/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
650-647-3643
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024